[Therapeutic options in hormone refractory prostate carcinoma]

Urologe A. 2000 May;39(3):267-73. doi: 10.1007/s001200050354.

[Article in German]

Authors

M Graefen¹, P Hammerer, A Haese, H Huland

Affiliation

¹ Klinik und Poliklinik für Urologie, Universitätsklinik Hamburg-Eppendorf.

PMID: 10872254
DOI: 10.1007/s001200050354

No abstract available

Publication types

Review

MeSH terms

Androgen Antagonists / adverse effects
Androgen Antagonists / therapeutic use*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Hormonal / adverse effects
Antineoplastic Agents, Hormonal / therapeutic use*
Clinical Trials as Topic
Humans
Male
Prognosis
Prostatic Neoplasms / mortality
Prostatic Neoplasms / therapy*
Survival Rate

Substances

Androgen Antagonists
Antineoplastic Agents
Antineoplastic Agents, Hormonal